Patient With Advanced Aggressive B2 Thymoma Achieved Positive Outcomes Post CAP-Endostar Combination Therapy [0.03%]
接受CAP化疗联合恩度治疗的晚期侵袭性B2型胸腺瘤患者的疗效分析
Min Zhang,Jingjing Zhang,Kelei Zhao et al.
Min Zhang et al.
This case report features a patient with an invasive thymoma. The patient presented with an anterior mediastinal mass that invaded the left brachiocephalic trunk vein, resulting in the formation of a carcinoma thrombus in the right atrium, ...
Explainable Machine Learning Predictions for the Benefit From Chemotherapy in Advanced Non-Small Cell Lung Cancer Without Available Targeted Mutations [0.03%]
用于无可用靶向突变的晚期非小细胞肺癌化疗获益的可解释机器学习预测模型
Zhao Shuang,Xiong Xingyu,Cheng Yue et al.
Zhao Shuang et al.
Background: Non-small cell lung cancer (NSCLC) is a global health challenge. Chemotherapy remains the standard therapy for advanced NSCLC without mutations, but drug resistance often reduces effectiveness. Developing more...
Rapid Response to Penpulimab Combined With Anlotinib and Chemotherapy in a Thoracic SMARCA4-UT Without PD-L1 Expression: A Case Report and Review of Literature [0.03%]
派普利单抗联合阿帕替尼和化疗快速起效治疗胸腔SMARCA4缺失型子宫内膜样癌肉瘤一例及文献复习
Yuanhang Wang,Kelei Zhao,Jingjing Zhang et al.
Yuanhang Wang et al.
SMARCA4-deficient undifferentiated tumor (SMARCA4-UT) in the chest is a high-grade malignant tumor that grows rapidly and often carries a poor prognosis. Unfortunately, there are currently no effective treatment available until now. Here, w...
A Meta-Analysis of Efficacy and Safety of Neoadjuvant Immunotherapy Plus Chemotherapy for Resectable Non-Small Cell Lung Cancer [0.03%]
新辅助免疫治疗联合化疗可切除非小细胞肺癌的疗效和安全性的Meta分析
Xinru Sun,Tianhua Kang,Baodong Liu et al.
Xinru Sun et al.
Introduction: Neoadjuvant immunotherapy plus chemotherapy has ushered in a new era for surgical treatment for patients with NSCLC. This study aimed to examine the efficacy and safety of neoadjuvant immunotherapy plus chem...
Evaluation of Efficacy and Safety in First-Line Treatment Methods for Extensive-Stage Small Cell Lung Cancer: A Comprehensive Comparative Study of Chemotherapy, Targeted Therapy Combined With Chemotherapy, and Immunotherapy Combined With Chemotherapy [0.03%]
广泛期小细胞肺癌一线治疗方式的疗效及安全性评估：化疗、靶向联合化疗和免疫联合化疗对比的全面研究
Tiantian Zhang,Lu Tao,Yufo Chen et al.
Tiantian Zhang et al.
Background: Small cell lung cancer (SCLC) is a highly aggressive tumor with limited effectiveness in its standard chemotherapy treatment. Targeted antiangiogenic therapy and immune checkpoint inhibitors (ICIs) have demons...
Comparative Study
The clinical respiratory journal. 2024 Aug;18(8):e13819. DOI:10.1111/crj.13819 2024
Nomogram for Predicting Efficacy and Prognosis After Chemotherapy for Advanced NSCLC [0.03%]
预测晚期NSCLC化疗疗效和预后的列线图
Jiaying Gao,Yandong Nan,Gang Liu et al.
Jiaying Gao et al.
Purpose: One major issue is the therapeutic effect following chemotherapy for non-small cell lung cancer (NSCLC). Although numerous risk factors have been identified and novel therapies have been developed, improving pati...
Treatment Adherence and Health Status of Patients With COPD Under Treatment With Salmeterol/Fluticasone via the Elpenhaler® Device: The AHEAD Study [0.03%]
有关使用昂丹司琼片预防或减轻癌症患者因化疗引起的恶心和呕吐的有效性和安全性的III期临床研究
Konstantinos P Exarchos,Georgios Hillas,Paschalis Steiropoulos et al.
Konstantinos P Exarchos et al.
Background: Chronic obstructive pulmonary disease (COPD) is a heterogeneous progressive lung condition characterized by long-term respiratory symptoms and airflow limitation. Appropriate bronchodilation is the cornerstone...
Observational Study
The clinical respiratory journal. 2024 Jul;18(7):e13803. DOI:10.1111/crj.13803 2024
Efficacy of neoadjuvant chemotherapy combined with surgery in patients with nonsmall cell lung cancer: A meta-analysis [0.03%]
非小细胞肺癌新辅助化疗联合手术疗效的meta分析研究进展
Hai-Jun Dong,Cheng-Yan Yang
Hai-Jun Dong
Introduction: This meta-analysis sought to investigate the effect of neoadjuvant chemotherapy (NACT) combined with surgery in patients with nonsmall cell lung cancer (NSCLC). ...
A prognostic signature for lung adenocarcinoma by five genes associated with chemotherapy in lung adenocarcinoma [0.03%]
五个与肺癌化疗相关的基因的预后特征用于肺腺癌
Xiaofeng Li,Chunwei Xu,Yonghua Min et al.
Xiaofeng Li et al.
Background: Lung adenocarcinoma (LUAD) is one of the most common subtypes of lung cancer. Finding prognostic biomarkers is helpful in stratifying LUAD patients with different prognosis. ...
Radioactive seeds insertion with chemotherapy for advanced non-small-cell lung cancer: A meta-analysis [0.03%]
放疗联合化疗治疗晚期非小细胞肺癌的荟萃分析研究
Hong Wu,Lei Li,Jing Yang et al.
Hong Wu et al.
Background: Non-small-cell lung cancers (NSCLCs) are only eligible to undergo curative surgical resection in